[Recurrent and chronic central serous chorioretinopathy. Retina thickness evaluation one month after intravitreal bevacizumab injection].

PURPOSE To evaluate the efficacy of intavitreal injection of bevacizumab in patients with chronic central serous chorioretinopathy. METHODS A study of 8 patients with central serous chorioretinopathy who were treated with intravitreal injection of bevacizumab. We studied the visual acuity with Snelleńs method and the foveal thickness, before and after the injection. RESULTS The mean age of the patients was 50.25 years. After one month of follow-up, visual acuity before the injection was 0.431 ± 0.249 vision lines and after was 0.631 ± 0.310 vision lines (P=.017).The foveal thickness was 351.25 ± 78.492 μm and after treatment was 183.50 ± 22.640 μm (P=.012). CONCLUSIONS Intravitreal bevacizumab can be an alternative treatment in patients with serous central chorioretinopathy as it leads to a better objective visual acuity and foveal thickness with optical coherence tomography.